142 related articles for article (PubMed ID: 35138498)
1. Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach.
Khashaba M; Fawzy M; Abdel-Aziz A; Eladawei G; Nagib R
J Egypt Natl Canc Inst; 2022 Feb; 34(1):6. PubMed ID: 35138498
[TBL] [Abstract][Full Text] [Related]
2. Better or worse? The prognostic role of the mesenchymal subtype in patients with high-grade serous ovarian carcinoma: A systematic review and meta-analysis.
Chen J; Shi X; Xiao L; Li Z; Li Z; Sun L
Cancer Med; 2022 Oct; 11(20):3761-3770. PubMed ID: 35434908
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.
Murakami R; Matsumura N; Mandai M; Yoshihara K; Tanabe H; Nakai H; Yamanoi K; Abiko K; Yoshioka Y; Hamanishi J; Yamaguchi K; Baba T; Koshiyama M; Enomoto T; Okamoto A; Murphy SK; Mori S; Mikami Y; Minamiguchi S; Konishi I
Am J Pathol; 2016 May; 186(5):1103-13. PubMed ID: 26993207
[TBL] [Abstract][Full Text] [Related]
4. The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R; Matsumura N; Michimae H; Tanabe H; Yunokawa M; Iwase H; Sasagawa M; Nakamura T; Tokuyama O; Takano M; Sugiyama T; Sawasaki T; Isonishi S; Takehara K; Nakai H; Okamoto A; Mandai M; Konishi I
Gynecol Oncol; 2019 May; 153(2):312-319. PubMed ID: 30853361
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognostic potential of histopathological subtyping in high-grade serous ovarian carcinoma.
Zelisse HS; Hwan RA; van de Vijver MJ; Dijk F; Mom CH; Hooijer GKJ; van Gent MDJM; Snijders MLH
Virchows Arch; 2024 Apr; ():. PubMed ID: 38622323
[TBL] [Abstract][Full Text] [Related]
6. Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.
Wang C; Armasu SM; Kalli KR; Maurer MJ; Heinzen EP; Keeney GL; Cliby WA; Oberg AL; Kaufmann SH; Goode EL
Clin Cancer Res; 2017 Aug; 23(15):4077-4085. PubMed ID: 28280090
[No Abstract] [Full Text] [Related]
7. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
[TBL] [Abstract][Full Text] [Related]
8. Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers.
Azzalini E; Barbazza R; Stanta G; Giorda G; Bortot L; Bartoletti M; Puglisi F; Canzonieri V; Bonin S
Gynecol Oncol; 2021 Dec; 163(3):498-505. PubMed ID: 34602289
[TBL] [Abstract][Full Text] [Related]
9. Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
Zeng H; Chen L; Zhang M; Luo Y; Ma X
Gynecol Oncol; 2021 Oct; 163(1):171-180. PubMed ID: 34275655
[TBL] [Abstract][Full Text] [Related]
10. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
[TBL] [Abstract][Full Text] [Related]
11. Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
Ohsuga T; Yamaguchi K; Kido A; Murakami R; Abiko K; Hamanishi J; Kondoh E; Baba T; Konishi I; Matsumura N
BMC Cancer; 2017 Aug; 17(1):580. PubMed ID: 28851311
[TBL] [Abstract][Full Text] [Related]
12. Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
Chen GM; Kannan L; Geistlinger L; Kofia V; Safikhani Z; Gendoo DMA; Parmigiani G; Birrer M; Haibe-Kains B; Waldron L
Clin Cancer Res; 2018 Oct; 24(20):5037-5047. PubMed ID: 30084834
[No Abstract] [Full Text] [Related]
13. Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).
Chung YS; Park SY; Lee JY; Park JY; Lee JW; Kim HS; Suh DS; Kim YH; Lee JM; Kim M; Choi MC; Shim SH; Lee KH; Song T; Hong JH; Lee WM; Lee B; Lee IH
BMC Cancer; 2019 Apr; 19(1):341. PubMed ID: 30971221
[TBL] [Abstract][Full Text] [Related]
14. Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging.
Miyagawa C; Nakai H; Otani T; Murakami R; Takamura S; Takaya H; Murakami K; Mandai M; Matsumura N
J Gynecol Oncol; 2023 Jul; 34(4):e47. PubMed ID: 36807749
[TBL] [Abstract][Full Text] [Related]
15. Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
Takaya H; Nakai H; Sakai K; Nishio K; Murakami K; Mandai M; Matsumura N
Gynecol Oncol; 2020 Feb; 156(2):415-422. PubMed ID: 31785864
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
[No Abstract] [Full Text] [Related]
18. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network.
Sehouli J; Braicu EI; Richter R; Denkert C; Jank P; Jurmeister PS; Kunze CA; Budczies J; Darb-Esfahani S; Schmitt WD; Traut A; Grabowski J; Taube ET; Plett H
Hum Pathol; 2019 Mar; 85():299-308. PubMed ID: 30428389
[TBL] [Abstract][Full Text] [Related]
20. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
